Inside the futuristic biotech startup Cellares that’s building a cure for cancer with $355 million in funding

two men in suits pose in front of the cell shuttle (Credit: Courtesy of Cellares)

New Jersey may not have the best reputation, perhaps sullied by inevitable comparisons to MTV’s Jersey Shore or the Sopranos. But what it does have is its critical role—albeit underrated—as a biotech hub. 

Competing with South San Francisco and Boston, New Jersey is among the leading global centers for biomedical research, home to some of the largest companies in the space from Johnson & Johnson to Bristol Myers Squibb. The region has also become a magnet for venture-backed startups seeking to revolutionize how we treat diseases.